知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.022 秒)

    POTASSIUM-BINDING AGENTS FOR TREATING HYPERTENSION AND HYPERKALEMIA
    5.
    发明申请
    POTASSIUM-BINDING AGENTS FOR TREATING HYPERTENSION AND HYPERKALEMIA 有权
    用于治疗高血压和高血压的钾结合剂

    公开(公告)号：US20170020916A1

    公开(公告)日：2017-01-26

    申请号：US15287179

    申请日：2016-10-06

    申请人： Relypsa, Inc.

    发明人： Gerrit Klaerner ,  Lance Berman

    IPC分类号： A61K31/78 ,  B01J39/20 ,  A61K9/14

    CPC分类号： A61K31/78 ,  A61K9/14 ,  A61K31/7004 ,  A61K33/06 ,  A61K33/24 ,  B01J39/20

    摘要： The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.

    摘要翻译： 本发明一般涉及在有需要的患者中治疗高血压（HTN）的方法，其中患者任选地进一步患有慢性肾脏疾病（CKD）或II型糖尿病（T2DM）。 本发明还涉及在有需要的患者中治疗高钾血症的方法，其中患者患有CKD，T2DM或HTN，并且任选地用有效量的肾素 - 血管紧张素 - 醛固酮系统（RAAS）药物治疗。 本发明还涉及在有需要的患者中治疗肾病的方​​法，其中所述患者任选地用有效量的肾素 - 血管紧张素 - 醛固酮系统（RAAS）药物治疗。 所述方法可以包括向患者施用有效量的结合钾的剂量以降低患者的血压和/或增加或稳定患者的肾功能。

    POTASSIUM BINDING POLYMERS FOR TREATING HYPERTENSION AND HYPERKALEMIA
    7.
    发明申请
    POTASSIUM BINDING POLYMERS FOR TREATING HYPERTENSION AND HYPERKALEMIA 审中-公开
    用于治疗高血压和高血压的钾结合聚合物

    公开(公告)号：US20140105848A1

    公开(公告)日：2014-04-17

    申请号：US14048983

    申请日：2013-10-08

    申请人： Relypsa, Inc.

    发明人： Gerrit Klaerner ,  Lance Berman

    IPC分类号： A61K31/78

    摘要： The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding polymer to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.

    摘要翻译： 本发明一般涉及在有需要的患者中治疗高血压（HTN）的方法，其中患者任选地进一步患有慢性肾脏病（CKD）或II型糖尿病（T2DM）。 本发明还涉及在有需要的患者中治疗高钾血症的方法，其中患者患有CKD，T2DM或HTN，并且任选地用有效量的肾素 - 血管紧张素 - 醛固酮系统（RAAS）药物治疗。 本发明还涉及在有需要的患者中治疗肾病的方​​法，其中所述患者任选地用有效量的肾素 - 血管紧张素 - 醛固酮系统（RAAS）药物治疗。 所述方法可以包括向患者施用有效量的结合钾的聚合物以降低患者的血压和/或增加或稳定患者的肾功能。

    Potassium-binding agents for treating hypertension and hyperkalemia
    9.
    发明授权
    Potassium-binding agents for treating hypertension and hyperkalemia 有权

    公开(公告)号：US09925212B2

    公开(公告)日：2018-03-27

    申请号：US15287179

    申请日：2016-10-06

    申请人： Relypsa, Inc.

    发明人： Gerrit Klaerner ,  Lance Berman

    IPC分类号： A61K9/00 ,  A61K31/78 ,  A61K31/7004 ,  A61K9/14 ,  A61K33/06 ,  A61K33/24 ,  B01J39/20

    CPC分类号： A61K31/78 ,  A61K9/14 ,  A61K31/7004 ,  A61K33/06 ,  A61K33/24 ,  B01J39/20

    摘要： The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.